Assessing the baseline burden of otitis media in children 2 to 3 years of age for estimating the effecfs of 13-valent pneumococcal conjugate vaccine (PCV) on otitis media

Autor: Njuma Libwea, J., Kobela, M., Koki Ndombo, P., Syrjänen, R., Huhtala, H., Fointama, N., Shiro, K., Nohynek, H., Nourti, P., Palmu, A.

Publikováno v: In International Journal of Infectious Diseases April 2016 45 Supplement 1:234-235

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Generating the evidence to support the establishment of a Respiratory Syncytial Virus surveillance system in Cameroon: A study protocol.

Autor: Njuma Libwea J; Directorate for Disease Control, Epidemics and Pandemics Ministry of Public Health, Yaoundé, Cameroon.; Cameroon Academy of Sciences, Yaoundé, Cameroon.; Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland.; African Science Frontiers Initiatives [ASFI], Lagos, Nigeria., Esso L; Directorate for Disease Control, Epidemics and Pandemics Ministry of Public Health, Yaoundé, Cameroon., Njoh AA; Central Coordination, Expanded Programme on Immunization, Yaoundé, Cameroon.; School of Global Health and Bioethics, Euclid University, Bangui, Central Africa Republic., Ngwa CH; African Science Frontiers Initiatives [ASFI], Lagos, Nigeria.; Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.; Global Action for Public Health Services (GAPS), Buea, Cameroon., Ngomba Armelle V; Directorate for Disease Control, Epidemics and Pandemics Ministry of Public Health, Yaoundé, Cameroon., Bilounga Ndongo C; Directorate for Disease Control, Epidemics and Pandemics Ministry of Public Health, Yaoundé, Cameroon., Etoundi Mballa GA; Directorate for Disease Control, Epidemics and Pandemics Ministry of Public Health, Yaoundé, Cameroon., Nwaru BI; African Science Frontiers Initiatives [ASFI], Lagos, Nigeria.; Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden., Weinberger D; Yale School of Public Health, New Haven, Connecticut, United States of America., Njouom R; Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.; Centre Pasteur of Cameroon, Yaoundé, Cameroon., Koulla-Shiro S; Centre Pasteur of Cameroon, Yaoundé, Cameroon.

Publikováno v: PloS one [PLoS One] 2024 Jun 11; Vol. 19 (6), pp. e0303468. Date of Electronic Publication: 2024 Jun 11 (Print Publication: 2024).

Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011-2018.

Autor: Njuma Libwea J; National Institute for Health and Welfare (THL), Helsinki, Finland.; Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland.; Expanded Programme on Immunization, Cameroon., Fletcher MA; Emerging Markets Medical Affairs, Vaccines, Pfizer, Inc, Paris, France., Koki Ndombo P; Expanded Programme on Immunization, Cameroon.; Mother & Child Hospital (MCH), Chantal Biya Foundation, Yaoundé, Cameroon., Boula A; Mother & Child Hospital (MCH), Chantal Biya Foundation, Yaoundé, Cameroon., Ashukem NT; Mother & Child Hospital (MCH), Chantal Biya Foundation, Yaoundé, Cameroon.; Ministry of Public Health, Yaoundé, Cameroon., Ngo Baleba M; Mother & Child Hospital (MCH), Chantal Biya Foundation, Yaoundé, Cameroon., Kingue Bebey RS; Mother & Child Hospital (MCH), Chantal Biya Foundation, Yaoundé, Cameroon., Nkolo Mviena EG; Mother & Child Hospital (MCH), Chantal Biya Foundation, Yaoundé, Cameroon., Tageube J; Mother & Child Hospital (MCH), Chantal Biya Foundation, Yaoundé, Cameroon., Kobela Mbollo M; Expanded Programme on Immunization, Cameroon.; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon., Koulla-Shiro S; Ministry of Public Health, Yaoundé, Cameroon.; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon., Madhi S; South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, Faculty of HealthSciences, University of the Witwatersrand, Johannesburg, South Africa., Njanpop-Lafourcade BM; Agence de Médicine Préventive (AMP), Paris, France., Mohammad A; Pfizer Vaccines Medical Development & Medical/Scientific Affairs, New York, New York, United States of America., Begier E; Pfizer Vaccines Medical Development & Medical/Scientific Affairs, New York, New York, United States of America., Southern J; Pfizer Vaccines Medical Development & Medical/Scientific Affairs, New York, New York, United States of America., Beavon R; Pfizer Vaccines Medical Development & Medical/Scientific Affairs, New York, New York, United States of America., Gessner B; Pfizer Vaccines Medical Development & Medical/Scientific Affairs, New York, New York, United States of America.

Publikováno v: PloS one [PLoS One] 2021 Apr 15; Vol. 16 (4), pp. e0250010. Date of Electronic Publication: 2021 Apr 15 (Print Publication: 2021).